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Abstract
Background: Colorectal cancer (CRC) is the most common form of cancer and the third leading cause of death in
Taiwan. Serum alpha-fetoprotein (AFP) has been extensively used as a biomarker for hepatocellular carcinoma (HCC)
and yolk sac tumors.
Case presentation: This case report presents a 90-year-old woman with right abdominal pain and poor appetite
for 1 week. The computed tomography (CT) showed wall thickening in the proximal ascending colon with
ruptured appendicitis. Preoperative serum AFP was high. There was no definite liver metastasis or other abnormal
findings in the hepatobiliary systems. After initial empirical antibiotic treatment, we performed laparoscopic right
hemicolectomy. The pathological assessment was poorly differentiated adenocarcinoma with neuroendocrine
differentiation in the ascending colon. The tumor cells did not produce AFP. Amazingly, the follow-up serum AFP
level 1 month after the surgery declined to normal range. The patient had an uneventful course after the surgery
and was free of recurrence or metastasis within 5 months of follow-up.
Conclusions: AFP may be a useful tumor marker in poorly differentiated colorectal cancer with neuroendocrine
component patients and a prediction of early treatment response.
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Background
Colorectal cancer (CRC) is the most common form of
cancer and the third leading cause of death in Taiwan.
Currently, more than 14,000 new cases of colorectal
cancer are diagnosed annually [1]. Serum alpha-
fetoprotein (AFP) has been extensively used as a bio-
marker for hepatocellular carcinoma (HCC) and yolk
sac tumors [2, 3]. Elevated serum levels of AFP were
also found in patients with carcinoma metastasis to
the liver or non-neoplastic liver injury. Some studies
have showed that the other tumors in human could
also produce AFP, and gastric cancer was one of the
most common [4]. Here, we report a rare case of
colon cancer in a patient with an elevated serum AFP
level. To the best of our knowledge, an elevated
serum level of AFP resulting from colon adenocarcin-
oma with neuroendocrine differentiation has not been
reported previously.
Case presentation
A 90-year-old woman presented to the emergency de-
partment at the local hospital having had an intermittent
abdominal pain with poor appetite for 1 week. Family
history for colorectal cancer was negative.
Preoperative imaging by abdominal computed tomog-
raphy (CT) at the local hospital showed an annular
tumor of 5.0 × 4.5 cm size in the ascending colon and
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wall thickening of the appendix, with peripheral fat
stranding (Fig. 1a, b). Ascending colon tumor with
ruptured appendicitis was diagnosed. There were no
hints for other distant metastases, as revealed by CT
and chest X-ray. Laboratory studies showed a
hemoglobin concentration of 6.8 g/dL, WBC count of
15,300/μL, platelet count of 412,000/μL, and C-reactive
protein level of 18.88 mg/dL. Standard serum tumor
marker carcinogenic antigen (CEA) and CA19-9 were
found normal, but AFP was elevated (90.1 ng/mL) ac-
cording to a cutoff of 20 ng/mL. The patient had
received 5-day intravenous empirical antibiotics in the
local hospital before admission.
After admission to our hospital, a series of survey was
performed, including abdominal CT (Fig. 1c). The gen-
eral examination was unremarkable, but localized right
lower quadrant abdominal tenderness, while laboratory
studies showed a hemoglobin concentration of 9.8 g/dL,
WBC count of 8000/μL, platelet count of 339,000/μL,
and C-reactive protein level of 2.76 mg/dL. Renal and
liver function tests were normal, and hepatitis B and C
markers were negative. Serum carcinoembryonic antigen
(CEA) and CA 19-9 levels were normal. However, AFP
was still elevated (64.9 ng/mL). After completing pre-
operative diagnostics, emergent laparoscopic surgery
was performed showing a fungating tumor involving
the proximal ascending colon and a localized abscess
between the terminal ileum and cecum, compatible
with ruptured appendicitis (Fig. 2a, b). So, we per-
formed laparoscopic right hemicolectomy with side-to-
side anastomosis.
The pathological assessment of the resected speci-
men showed a 5 × 4 cm fungating tumor consisting
of a poorly differentiated adenocarcinoma with neu-
roendocrine differentiation extending through the
visceral peritoneum. Extramural vascular invasion of
the adenocarcinoma cells was present. Microscopic
evaluation of the 20 regional lymph nodes in the
mesentery of the resected colon revealed four lymph
nodes involvement. By immunohistochemistry, the
cells were positive stained for CD20, CDX-2, synap-
tophysin, and negative for AFP, CD7, CD56, neuron-
specific enolase, and chromogranin A. Morphologic
and immunohistochemical findings confirmed the
diagnosis of poorly differentiated adenocarcinoma
with neuroendocrine differentiation within the as-
cending colon tumor and mesenteric lymph nodes.
K-RAS and B-RAF genetic mutations were deter-
mined for primary tumor DNA after microdissection,
and both genes were wild type. In summary, histo-
logical and immunohistochemical specifications fi-
nally revealed diagnosis of a poorly differentiated
adenocarcinoma with neuroendocrine differentiation
in the ascending colon and ruptured appendicitis.
The final tumor stage was pT4aN2aM0, stage IIIc.
In the postoperative course with the ordinary ward, re-
covery with oral feeding starting at the fourth postopera-
tive day was uneventful, the patient could be sent home
11 days after surgery. After discussion of this case in a
multidisciplinary team treatment combined conference
for colorectal cancer, the patient decided not to receive
adjuvant chemotherapy because she was too weak to tol-
erate adjuvant chemotherapy. Interestingly, serum AFP
level 1 month after the surgery declined to 1.99 ng/mL,
used as tumor marker for recurrence. Other tumor
markers (such as CEA and CA19-9) remained within the
normal range during follow-up. Subsequent clinical and
imaging follow-up revealed no signs of tumor recurrence
up to now.
Discussion
To our knowledge, this report is the first case of a poorly
differentiated adenocarcinoma with neuroendocrine dif-
ferentiation in the colonic segment, combined with an
elevated serum AFP level. Surgery is the only treatment
that has the potential to cure patients with CRC. In our
Fig. 1 CT scans of the abdomen. An enhanced abdominal CT scan indicated wall thickening of the ascending colon, compatible with colon
cancer (a, arrow), a swelling appendix with localized abscess, compatible with ruptured appendicitis (b, arrow), and regression of appendicular
abscess after antibiotics treatment (c)
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case, there were no histopathological features and
patterns of immunoreactivity typically usually seen in
hepatoid adenocarcinoma.
In Taiwan, there is a large population of patients with
hepatitis B or C virus infection. AFP is a tumor marker
for HCC and had been used in the clinical practice for a
long time. The high levels of AFP in this patient origin-
ally raised the question as to whether there was a tumor
or another condition causing the expression of AFP. In
our case, we performed CT image twice with no definite
liver metastasis or hepatobiliary lesions.
To date, there is only limited data on most tumor
markers measured in neuroendocrine tumor (NET) pa-
tients, which has thus created uncertainty about their
role. According to the WHO classification, adenocarcin-
oma with neuroendocrine differentiation is distinguished
from neuroendocrine carcinoma by <30 % of the neuro-
endocrine component [5]. Although overall AFP is
elevated only in a minority of NET patient, this data
analysis demonstrates the ability of AFP to highlight a
group of NET patients with aggressive, high-grade tu-
mors, and poor prognosis. Thus, AFP is likely to be a
marker of tumor cell de-differentiation rather than a
marker of hepatic metastases from NETs [3].
This was important for diagnosis of hepatoid adeno-
carcinoma, including immunoreactive AFP in the
cytoplasm of cells in the trabecular or solid nests. In
the aspect of growth pattern, poorly differentiated
adenocarcinoma of solid type, small cell neuroendo-
crine cell carcinoma was similar to hepatoid adeno-
carcinoma. However, these tumors did not contain
any cells positive for AFP, as our present case. There-
fore, the diagnosis of hepatoid adenocarcinoma should
be strictly based on combination of hepatoid features
and AFP secretion.
In SEER database, the prognosis of adenocarcinoma
with neuroendocrine differentiation (>30 % adenocar-
cinoma and <30 % neuroendocrine component) was
closer to neuroendocrine carcinoma than to non-
neuroendocrine high-grade adenocarcinoma [6]. This
subtype of CRC was thought as high recurrence
rates, especially liver metastasis. Relatively poor sur-
vival in poorly differentiated adenocarcinoma with
neuroendocrine differentiation warrants studies of
adjuvant systemic therapy. In our case, serum AFP
levels were used as an indicator of therapeutic effect-
iveness and a marker for monitoring early recurrence
and metastasis. The serum AFP levels apparently cor-
related with the tumor burden, and increasing AFP
levels might give a warning for timely interventions.
Conclusions
In this study, we demonstrated a patient with poorly
differentiated adenocarcinoma with neuroendocrine
differentiation in the ascending colon, with an ele-
vated serum AFP. After curative radical colectomy,
AFP declined to normal range. AFP may be a useful
tumor marker in poorly differentiated CRC with neu-
roendocrine component patients, for early detection
of tumor recurrence.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images.
Abbreviations
AFP: alpha-fetoprotein; CEA: carcinogenic antigen; CRC: colorectal
cancer; CT: computed tomography; HCC: hepatocellular carcinoma;
NET: neuroendocrine tumor.
Fig. 2 Resected ascending tumor. Gross appearance of the ascending colon tumor and ruptured appendicitis (a, b)
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